Active Ingredient History
Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Through oral administration, fimasartan blocks angiotensin II receptor type 1 (AT1 receptors), reducing pro-hypertensive actions of angiotensin II, such as systemic vasoconstriction and water retention by the kidneys. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea on September 9, 2010, and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Aortic Stenosis, Subvalvular (Phase 4)
Atherosclerosis (Phase 4)
Blood Pressure (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Diabetes Mellitus (Phase 1)
Diabetes Mellitus, Type 2 (Phase 4)
Drug Interactions (Phase 1)
Dyslipidemias (Phase 3)
Essential Hypertension (Phase 4)
Healthy Volunteers (Phase 1)
Hypercholesterolemia (Phase 3)
Hyperlipidemias (Phase 1)
Hypertension (Phase 4)
Intermittent Claudication (Phase 1)
Ischemic Stroke (Phase 4)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Pharmacokinetics (Phase 1)
Renal Insufficiency, Chronic (Phase 3)
Renin-Angiotensin System (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue